Cargando…

Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity

The absence of fucose on asparagine-297 of the human immunoglobulin G (IgG) heavy chain has been shown to enhance antibody-dependent cellular cytotoxicity (ADCC) activity by 10- to 100-fold compared to fucosylated antibody. Our lab is studying the use of adeno-associated virus (AAV) as a vector for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Termini, James M., Martinez-Navio, José M., Gao, Guangping, Fuchs, Sebastian P., Desrosiers, Ronald C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782200/ https://www.ncbi.nlm.nih.gov/pubmed/33426147 http://dx.doi.org/10.1016/j.omtm.2020.11.001

Ejemplares similares

Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
por: Martinez-Navio, José M., et al.
Publicado: (2020)

AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity
por: Fuchs, Sebastian P., et al.
Publicado: (2015)

Recombinant AAV Vectors for Enhanced Expression of Authentic IgG
por: Fuchs, Sebastian P., et al.
Publicado: (2016)

Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys
por: Fuchs, Sebastian P., et al.
Publicado: (2019)

High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes
por: Gardner, Matthew R., et al.
Publicado: (2022)

Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies
por: Gardner, Matthew R., et al.
Publicado: (2019)

In Vitro Glycoengineering of IgG1 and Its Effect on Fc Receptor Binding and ADCC Activity
por: Thomann, Marco, et al.
Publicado: (2015)

Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
por: Fuchs, Sebastian P, et al.
Publicado: (2016)

Editorial: “AAV Gene Therapy: Immunology and Immunotherapeutics”
por: Martinez-Navio, José M., et al.
Publicado: (2021)

A Monoclonal Antibody Produced in Glycoengineered Plants Potently Neutralizes Monkeypox Virus
por: Esqueda, Adrian, et al.
Publicado: (2023)

Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody
por: Falck, David, et al.
Publicado: (2020)

Evaluation of a glycoengineered monoclonal antibody via LC-MS analysis in combination with multiple enzymatic digestion
por: Liu, Renpeng, et al.
Publicado: (2015)

Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus
por: Vlahava, Virginia-Maria, et al.
Publicado: (2021)

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
por: Dixon, Kate J., et al.
Publicado: (2021)

The Yin and Yang of ADCC-Mediating Antibodies
por: Robert-Guroff, Marjorie
Publicado: (2016)

Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
por: Li, Wei, et al.
Publicado: (2017)

Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
por: Li, Shasha, et al.
Publicado: (2021)

rAAV-delivered PTEN therapeutics for prostate cancer
por: Ai, Jianzhong, et al.
Publicado: (2021)

A versatile design platform for glycoengineering therapeutic antibodies
por: Ludwig, Seth D., et al.
Publicado: (2022)

Increased monocyte-mediated antibody-dependent cellular cytotoxicity (ADCC) in Hodgkin's disease.
por: Pehamberger, H., et al.
Publicado: (1980)

Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms
por: Wada, Ryuta, et al.
Publicado: (2018)

In vitro and in vivo efficacy of anti‐chikungunya virus monoclonal antibodies produced in wild‐type and glycoengineered Nicotiana benthamiana plants
por: Hurtado, Jonathan, et al.
Publicado: (2019)

Expression and Display of Glycoengineered Antibodies and Antibody Fragments with an Engineered Yeast Strain
por: Shenoy, Anjali, et al.
Publicado: (2021)

The Applications of Metabolic Glycoengineering
por: Ying, Liwei, et al.
Publicado: (2022)

Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation
por: Crooks, Ema T., et al.
Publicado: (2018)

Antibody Light Chains: Key to Increased Monoclonal Antibody Yields in Expi293 Cells?
por: Gong, Siqi, et al.
Publicado: (2022)

ADCC potency assay: increased standardization with modified lymphocytes
por: Bretaudeau, Laurent, et al.
Publicado: (2011)

Genetic glycoengineering in mammalian cells
por: Narimatsu, Yoshiki, et al.
Publicado: (2021)

Strategies for Glycoengineering Therapeutic Proteins
por: Dammen-Brower, Kris, et al.
Publicado: (2022)

A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies
por: Lallemand, Christophe, et al.
Publicado: (2017)

Interaction analysis of glycoengineered antibodies with CD16a: a native mass spectrometry approach
por: Hajduk, Joanna, et al.
Publicado: (2020)

Cyclopropene derivatives of aminosugars for metabolic glycoengineering
por: Hassenrück, Jessica, et al.
Publicado: (2019)

Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC
por: Natsume, Akito, et al.
Publicado: (2009)

Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway
por: Mielke, Dieter, et al.
Publicado: (2019)

Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes
por: Pollara, J, et al.
Publicado: (2012)

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
por: Fox, Edward, et al.
Publicado: (2020)

Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors
por: Harada, Takeshi, et al.
Publicado: (2013)

ADCC-activating antibodies correlate with decreased risk of congenital human cytomegalovirus transmission
por: Semmes, Eleanor C., et al.
Publicado: (2023)

Role of Acetylsalicylic Acid in Cytokine Stimulation of Macrophages in Antibody-Dependent Cellular Cytotoxicity (ADCC)
por: Jäpel, M., et al.
Publicado: (1994)

Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma
por: Li, Qi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pjs8rsbuu2le6dfnae5c7rljhn